Add Trial
Sign In

A Randomized, Phase 3 Trial With Anti-PD-1 Monoclonal Antibody Pembrolizumab (MK-3475) Versus Placebo for Patients With Early Stage NSCLC After Resection and Completion of Standard Adjuvant Therapy (PEARLS)


Study Type Treatment
Sponsor Name Merck
Disease type Non-Small Cell Lung Cancer
Disease Stage IB – IIIA
Clinical Status Adjuvant
Phase III
Intervention / Treatment Pembrolizumab versus Placebo
Research Site Charles-LeMoyne Hospital
Investigator Dre Flavia De Angelis
Coordinator Amélie Valcourt
Telephone number
Fax number
Study start date November 6, 2015
Study end date
Trial Status Recruiting

Listing Features


Working Hours :

Now Closed UTC - 4

Price / Claim :

Recruit a patient:

*for confidentiality, do not include the name of the patient

*pour raisons de confidentialité, n'incluez pas le nom du patient

Hosted by :

Claim listing: MK-3475-091/KEYNOTE-091 (PEARLS)

Our website is under development. We're sorry for any inconvenience that might appear.Notre site web est en cours de développement. Nous sommes désolés pour tout inconvénient qui pourrait survenir.

Reply to Message


Account details will be confirmed via email.

Reset Your Password